Roof Eidam Maycock Peralta LLC Purchases New Stake in Merck & Co., Inc. $MRK

Key Points

• Roof Eidam Maycock Peralta LLC purchased a new stake of 13,075 shares (~$1.376M) in Merck during Q4; several other funds also increased positions and institutional investors now own 76.07% of the stock.
• Merck beat quarterly expectations (EPS $2.04 vs. $2.01; revenue $16.40B vs. $16.19B) and set FY2026 EPS guidance of 5.00–5.15, while analysts forecast about 9.01 EPS for the current fiscal year.
• Insiders have been net sellers (CFO and CEO sold large blocks on Feb. 4; insiders sold ~320,176 shares worth $38.3M over 90 days), even as firms like UBS raised their price target to $145 and the consensus rating is a Moderate Buy (average target ~$128.47).

Roof Eidam Maycock Peralta LLC purchased a new stake in Merck & Co., Inc. (NYSE:MRK - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 13,075 shares of the company's stock, valued at approximately $1,376,000.

Several other hedge funds have also added to or reduced their stakes in MRK. Chemung Canal Trust Co. raised its position in shares of Merck & Co., Inc. by 21.1% during the third quarter. Chemung Canal Trust Co. now owns 76,338 shares of the company's stock worth $6,407,000 after purchasing an additional 13,285 shares during the period. First Pacific Financial raised its position in shares of Merck & Co., Inc. by 14.7% during the third quarter. First Pacific Financial now owns 47,555 shares of the company's stock worth $3,991,000 after purchasing an additional 6,082 shares during the period. Diversified Trust Co raised its position in shares of Merck & Co., Inc. by 9.6% during the third quarter. Diversified Trust Co now owns 207,838 shares of the company's stock worth $17,444,000 after purchasing an additional 18,187 shares during the period. Farther Finance Advisors LLC raised its position in shares of Merck & Co., Inc. by 48.9% during the fourth quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company's stock worth $10,296,000 after purchasing an additional 32,114 shares during the period. Finally, Coldstream Capital Management Inc. raised its position in shares of Merck & Co., Inc. by 12.7% during the third quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company's stock worth $10,364,000 after purchasing an additional 13,940 shares during the period. Institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Stock Down 2.1%

Shares of Merck & Co., Inc. stock opened at $115.42 on Friday. The business's 50 day simple moving average is $119.18 and its 200 day simple moving average is $105.58. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14. The firm has a market cap of $285.07 billion, a PE ratio of 15.85, a P/E/G ratio of 2.37 and a beta of 0.26. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The business had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. During the same quarter last year, the firm earned $1.72 EPS. Merck & Co., Inc.'s revenue for the quarter was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th were paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date was Monday, March 16th. Merck & Co., Inc.'s dividend payout ratio (DPR) is currently 46.70%.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: UBS raised its price target on MRK to $145, which is a direct positive signal from a major sell-side firm and can lift investor sentiment. UBS Boosts MRK Price Target
• Positive Sentiment: Zacks highlights Keytruda as the primary growth driver heading into Q1 results, noting new indications and uptake that could sustain revenue growth — this supports medium-term earnings expectations. Will Keytruda Continue to Aid Merck's Top Line?
• Positive Sentiment: Market chatter and technical traders are bullish on MRK; an options/technical piece highlights a bullish diagonal trade targeting $130, reflecting some traders positioning for a near-term rebound. Bullish Diagonal Trade Targets $130
• Neutral Sentiment: Zacks/Yahoo attention pieces note MRK is a trending stock and recap key facts (pipeline, Keytruda dependence, valuation) — useful for retail interest but not new company-specific catalysts. Merck Is a Trending Stock
• Neutral Sentiment: Industry reports cite Merck among major players in the animal-health market outlook — this is incremental, long-term relevance rather than an immediate stock driver. Animal Health Market Intelligence Report
• Neutral Sentiment: Coverage of Merck KGaA XTRA: MRK valuation can create ticker/name confusion for casual readers but has no direct impact on U.S.-listed Merck & Co. fundamentals. Assessing Merck KGaA Valuation
• Neutral Sentiment: Other healthcare staffing and small-cap biotech headlines in the feed (Soleo Health, Summit Therapeutics) are peripheral and unlikely to move MRK stock materially. Soleo Health Appointment Summit Therapeutics BLA Acceptance

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on MRK shares. UBS Group raised their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a research report on Monday. Citigroup lifted their target price on Merck & Co., Inc. from $120.00 to $125.00 and gave the company a "neutral" rating in a research report on Friday, March 20th. Royal Bank Of Canada reissued an "outperform" rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a research report on Monday, March 30th. TD Cowen lifted their target price on Merck & Co., Inc. from $100.00 to $120.00 and gave the company a "hold" rating in a research report on Tuesday, January 20th. Finally, Wall Street Zen raised Merck & Co., Inc. from a "hold" rating to a "buy" rating in a research report on Saturday, March 28th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of "Moderate Buy" and an average price target of $128.47.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, CFO Caroline Litchfield sold 41,997 shares of the firm's stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $119.61, for a total value of $5,023,261.17. Following the completion of the transaction, the chief financial officer directly owned 90,192 shares in the company, valued at $10,787,865.12. This trade represents a 31.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Robert M. Davis sold 47,434 shares of the firm's stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $118.04, for a total value of $5,599,109.36. Following the completion of the transaction, the chief executive officer owned 443,602 shares of the company's stock, valued at approximately $52,362,780.08. This represents a 9.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 320,176 shares of company stock valued at $38,281,735. 0.13% of the stock is owned by insiders.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.